-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Acurx Pharmaceuticals (NASDAQ:ACXP) Receives New Coverage From Analysts at HC Wainwright
Acurx Pharmaceuticals (NASDAQ:ACXP) Receives New Coverage From Analysts at HC Wainwright
HC Wainwright initiated coverage on shares of Acurx Pharmaceuticals (NASDAQ:ACXP – Get Rating) in a report released on Monday morning, The Fly reports. The firm issued a buy rating and a $14.00 price objective on the stock.
Separately, Alliance Global Partners started coverage on shares of Acurx Pharmaceuticals in a report on Thursday, October 20th. They issued a buy rating on the stock.
Get Acurx Pharmaceuticals alerts:Acurx Pharmaceuticals Stock Down 1.6 %
Acurx Pharmaceuticals stock opened at $3.77 on Monday. Acurx Pharmaceuticals has a 52 week low of $2.33 and a 52 week high of $4.89. The firm's 50-day simple moving average is $3.19 and its 200 day simple moving average is $3.48. The firm has a market capitalization of $43.71 million, a PE ratio of -3.52 and a beta of -0.73.
Acurx Pharmaceuticals (NASDAQ:ACXP – Get Rating) last released its earnings results on Monday, November 14th. The company reported ($0.32) earnings per share (EPS) for the quarter.Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the stock. Semmax Financial Advisors Inc. increased its position in Acurx Pharmaceuticals by 365.5% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 5,879 shares of the company's stock worth $28,000 after purchasing an additional 4,616 shares in the last quarter. Castle Wealth Management LLC acquired a new stake in Acurx Pharmaceuticals in the second quarter valued at approximately $49,000. BlackRock Inc. grew its position in Acurx Pharmaceuticals by 149.8% in the first quarter. BlackRock Inc. now owns 16,699 shares of the company's stock valued at $55,000 after acquiring an additional 10,014 shares in the last quarter. Finally, Armistice Capital LLC acquired a new stake in Acurx Pharmaceuticals in the third quarter valued at approximately $3,198,000. Institutional investors and hedge funds own 3.03% of the company's stock.
About Acurx Pharmaceuticals
(Get Rating)
Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections.
Featured Stories
- Get a free copy of the StockNews.com research report on Acurx Pharmaceuticals (ACXP)
- Will Tesla Shares Rally If Musk Steps Down From Twitter?
- 5 Down But Not Out Stocks To Watch For 2023
- Can Chewy Fetch Double Digit Gains in 2023?
- Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
- Madrigal Pharmaceuticals Stock Is Up 200% In One Day, Here's Why
Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
HC Wainwright initiated coverage on shares of Acurx Pharmaceuticals (NASDAQ:ACXP – Get Rating) in a report released on Monday morning, The Fly reports. The firm issued a buy rating and a $14.00 price objective on the stock.
據The Fly報道，HC Wainwright在週一上午發佈的一份報告中發起了對Acurx製藥(納斯達克：ACXP-GET評級)股票的報道。該公司對該股發佈了買入評級和14.00美元的目標價。
Separately, Alliance Global Partners started coverage on shares of Acurx Pharmaceuticals in a report on Thursday, October 20th. They issued a buy rating on the stock.
另外，Alliance Global Partners在10月20日星期四的一份報告中開始報道Acurx製藥公司的股票。他們對這只股票發佈了買入評級。
Acurx Pharmaceuticals Stock Down 1.6 %
Acurx製藥類股下跌1.6%
Acurx Pharmaceuticals stock opened at $3.77 on Monday. Acurx Pharmaceuticals has a 52 week low of $2.33 and a 52 week high of $4.89. The firm's 50-day simple moving average is $3.19 and its 200 day simple moving average is $3.48. The firm has a market capitalization of $43.71 million, a PE ratio of -3.52 and a beta of -0.73.
Acurx製藥公司的股票週一開盤報3.77美元。Acurx PharmPharmticals的52周低點為2.33美元，52周高點為4.89美元。該公司的50日簡單移動均線切入位為3.19美元，200日簡單移動均線切入位為3.48美元。該公司市值為4,371萬美元，本益比為-3.52，貝塔係數為-0.73。
Institutional Inflows and Outflows
機構資金流入和流出
Institutional investors and hedge funds have recently modified their holdings of the stock. Semmax Financial Advisors Inc. increased its position in Acurx Pharmaceuticals by 365.5% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 5,879 shares of the company's stock worth $28,000 after purchasing an additional 4,616 shares in the last quarter. Castle Wealth Management LLC acquired a new stake in Acurx Pharmaceuticals in the second quarter valued at approximately $49,000. BlackRock Inc. grew its position in Acurx Pharmaceuticals by 149.8% in the first quarter. BlackRock Inc. now owns 16,699 shares of the company's stock valued at $55,000 after acquiring an additional 10,014 shares in the last quarter. Finally, Armistice Capital LLC acquired a new stake in Acurx Pharmaceuticals in the third quarter valued at approximately $3,198,000. Institutional investors and hedge funds own 3.03% of the company's stock.
機構投資者和對沖基金最近調整了對該股的持有量。Semmax金融顧問公司在第二季度將其在Acurx製藥公司的持倉增加了365.5%。Semmax Financial Advisors Inc.現在持有該公司5,879股股票，價值28,000美元，該公司在上個季度又購買了4,616股股票。Castle Wealth Management LLC在第二季度收購了Acurx製藥公司的新股份，價值約4.9萬美元。今年第一季度，貝萊德在艾柯克製藥的持倉增加了149.8%。貝萊德股份有限公司在上個季度增持了10,014股後，現在持有16,699股該公司股票，價值55,000美元。最後，停戰資本有限責任公司在第三季度收購了Acurx製藥公司的新股份，價值約為319.8萬美元。機構投資者和對沖基金持有該公司3.03%的股票。
About Acurx Pharmaceuticals
關於Acurx製藥公司
(Get Rating)
(獲取評級)
Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections.
Acurx製藥公司是一家臨床階段的生物製藥公司，開發用於治療細菌感染的抗生素。它的主要候選抗生素是ibezapolstat，這是一種新的作用機制，針對的是聚合酵素IIIC酵素，該酵素已經完成了治療艱難梭菌感染的IIa期臨床試驗。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Acurx Pharmaceuticals (ACXP)
- Will Tesla Shares Rally If Musk Steps Down From Twitter?
- 5 Down But Not Out Stocks To Watch For 2023
- Can Chewy Fetch Double Digit Gains in 2023?
- Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
- Madrigal Pharmaceuticals Stock Is Up 200% In One Day, Here's Why
- 免費獲取StockNews.com關於Acurx製藥的研究報告(ACXP)
- 如果馬斯克退出Twitter，特斯拉的股價會上漲嗎？
- 2023年值得關注的5個下跌但不是下跌的股票
- Chewy能否在2023年獲得兩位數的增長？
- 禮來公司預計將實現持久增長，儘管面臨眼前的挑戰
- Madrigal製藥公司的股票在一天內上漲了200%，原因如下
Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
獲得Acurx製藥日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Acurx製藥和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧